JP2022544050A5 - - Google Patents
Info
- Publication number
- JP2022544050A5 JP2022544050A5 JP2022505553A JP2022505553A JP2022544050A5 JP 2022544050 A5 JP2022544050 A5 JP 2022544050A5 JP 2022505553 A JP2022505553 A JP 2022505553A JP 2022505553 A JP2022505553 A JP 2022505553A JP 2022544050 A5 JP2022544050 A5 JP 2022544050A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- antibody
- seq
- amino acid
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025024929A JP7858104B2 (ja) | 2019-07-30 | 2025-02-19 | 抗ヒトｐ４０タンパク質ドメイン抗体及びその使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910706137 | 2019-07-30 | ||
| CN201910706137.1 | 2019-07-30 | ||
| CN201911040745 | 2019-10-29 | ||
| CN201911040745.X | 2019-10-29 | ||
| CN201911171754 | 2019-11-25 | ||
| CN201911171754.2 | 2019-11-25 | ||
| PCT/CN2020/105039 WO2021018114A1 (zh) | 2019-07-30 | 2020-07-28 | 抗人p40蛋白域抗体及其用途 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025024929A Division JP7858104B2 (ja) | 2019-07-30 | 2025-02-19 | 抗ヒトｐ４０タンパク質ドメイン抗体及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022544050A JP2022544050A (ja) | 2022-10-17 |
| JP2022544050A5 true JP2022544050A5 (enExample) | 2023-08-08 |
| JP7638955B2 JP7638955B2 (ja) | 2025-03-04 |
Family
ID=73735954
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022505553A Active JP7638955B2 (ja) | 2019-07-30 | 2020-07-28 | 抗ヒトｐ４０タンパク質ドメイン抗体及びその使用 |
| JP2025024929A Active JP7858104B2 (ja) | 2019-07-30 | 2025-02-19 | 抗ヒトｐ４０タンパク質ドメイン抗体及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025024929A Active JP7858104B2 (ja) | 2019-07-30 | 2025-02-19 | 抗ヒトｐ４０タンパク質ドメイン抗体及びその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12595300B2 (enExample) |
| EP (2) | EP4744731A2 (enExample) |
| JP (2) | JP7638955B2 (enExample) |
| KR (1) | KR20220038775A (enExample) |
| CN (1) | CN112079922B (enExample) |
| AU (1) | AU2020320910A1 (enExample) |
| BR (1) | BR112022001632A2 (enExample) |
| CA (1) | CA3145909A1 (enExample) |
| IL (1) | IL290167A (enExample) |
| MX (1) | MX2022001305A (enExample) |
| PH (1) | PH12022550223A1 (enExample) |
| WO (1) | WO2021018114A1 (enExample) |
| ZA (1) | ZA202202380B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022001305A (es) | 2019-07-30 | 2022-05-06 | Akeso Biopharma Inc | Anticuerpo de dominio proteínico p40 anti-humana y uso del mismo. |
| CN118620077B (zh) * | 2024-08-13 | 2024-11-12 | 苏州百道医疗科技有限公司 | 一种抗p40重组兔单克隆抗体及其应用 |
| WO2026062296A1 (en) * | 2024-09-23 | 2026-03-26 | Ose Immunotherapeutics | Therapy by antagonizing il-7 or cd127, and il-12, il-23, il-12r or il-23r |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| WO1988001649A1 (en) | 1986-09-02 | 1988-03-10 | Genex Corporation | Single polypeptide chain binding molecules |
| US6902734B2 (en) | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
| CN103146708A (zh) * | 2005-06-30 | 2013-06-12 | Abbvie公司 | Il-12/p40结合蛋白 |
| WO2009114040A2 (en) * | 2007-09-28 | 2009-09-17 | Centocor Ortho Biotech Inc. | Anti-il-12/23p40 antibodies, epitopes, formulations, compositions, methods and uses |
| KR20160116056A (ko) * | 2008-08-14 | 2016-10-06 | 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 | 항-ｉｌ-12/ｉｌ-23 항체 |
| TW201233395A (en) * | 2010-10-06 | 2012-08-16 | Abbott Lab | Methods for treating psoriasis |
| JP2014506132A (ja) | 2011-01-07 | 2014-03-13 | アッヴィ・インコーポレイテッド | 抗ｉｌ−１２／ｉｌ−２３抗体およびその使用 |
| PT2692865E (pt) * | 2012-07-30 | 2015-02-06 | Nbe Therapeutics Llc | Identificação mediada por transposição de proteínas funcionais ou de ligação específicas |
| RU2015122228A (ru) * | 2012-12-12 | 2017-01-19 | Васкулокс Инк. | Терапевтические антитела к CD47 |
| CN103275222B (zh) | 2013-05-15 | 2014-04-16 | 中山康方生物医药有限公司 | 一种阻断白介素12 p40功能的单克隆抗体及其编码基因和应用 |
| CN105294863B (zh) * | 2015-11-13 | 2019-01-22 | 叶才果 | 双功能抗体及其用途 |
| TW201922780A (zh) | 2017-09-25 | 2019-06-16 | 美商健生生物科技公司 | 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法 |
| GB201720351D0 (en) | 2017-12-06 | 2018-01-17 | Iontas Ltd | Selecting for developability in drug discovery |
| MX2022001305A (es) | 2019-07-30 | 2022-05-06 | Akeso Biopharma Inc | Anticuerpo de dominio proteínico p40 anti-humana y uso del mismo. |
-
2020
- 2020-07-28 MX MX2022001305A patent/MX2022001305A/es unknown
- 2020-07-28 CA CA3145909A patent/CA3145909A1/en active Pending
- 2020-07-28 AU AU2020320910A patent/AU2020320910A1/en active Pending
- 2020-07-28 KR KR1020227006902A patent/KR20220038775A/ko not_active Ceased
- 2020-07-28 WO PCT/CN2020/105039 patent/WO2021018114A1/zh not_active Ceased
- 2020-07-28 EP EP26169560.5A patent/EP4744731A2/en active Pending
- 2020-07-28 CN CN202010740669.XA patent/CN112079922B/zh active Active
- 2020-07-28 EP EP20847243.1A patent/EP4008727A4/en active Pending
- 2020-07-28 US US17/631,797 patent/US12595300B2/en active Active
- 2020-07-28 JP JP2022505553A patent/JP7638955B2/ja active Active
- 2020-07-28 PH PH1/2022/550223A patent/PH12022550223A1/en unknown
- 2020-07-28 BR BR112022001632A patent/BR112022001632A2/pt unknown
-
2022
- 2022-01-27 IL IL290167A patent/IL290167A/en unknown
- 2022-02-24 ZA ZA2022/02380A patent/ZA202202380B/en unknown
-
2025
- 2025-02-19 JP JP2025024929A patent/JP7858104B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110050000B (zh) | 含有TGF-β受体的融合蛋白及其医药用途 | |
| JP2021526022A5 (enExample) | ||
| US10662250B2 (en) | Humanized monoclonal antibody specific to syndecan-1 | |
| CN112512550A (zh) | 一种TGF-β受体融合蛋白药物组合物及其用途 | |
| RU2019139093A (ru) | Фармацевтическая композиция на основе антитела к pd-l1 и ее применение | |
| RU2019104980A (ru) | Анти-icos антитела | |
| KR20090088878A (ko) | 신규한 항증식 항체 | |
| JP2025114620A5 (enExample) | ||
| JP2020522281A5 (enExample) | ||
| US11965037B2 (en) | Anti-HER3 humanized monoclonal antibody | |
| JP2024540148A5 (enExample) | ||
| JP2025026839A (ja) | Ｍｕｃ１８に特異的な抗体 | |
| CN115819592A (zh) | 靶向ror1的抗原结合蛋白 | |
| JP2021524255A5 (enExample) | ||
| CN119487079A (zh) | 一种pvrig/tigit双特异性抗体药物组合物及其用途 | |
| CN113906053A (zh) | 抗cea抗体及其应用 | |
| JP7072703B6 (ja) | Ａｘｌタンパク質に結合する抗体 | |
| AU2016318158A1 (en) | Anti-survivin antibodies for cancer therapy | |
| CN109879966B (zh) | 基于鼠源cd19抗体的人源化设计及表达验证 | |
| JP7643752B2 (ja) | 抗ｐｄ－ｌ１抗体およびその用途 | |
| CN120554514A (zh) | 一种靶向人的叶酸受体α的单克隆抗体 | |
| CN112969715B (zh) | 一种抗cd47抗原结合蛋白及其应用 | |
| TW201840585A (zh) | 用於白斑病的治療的抗人cxcr3抗體 | |
| CN121752596A (zh) | 一种包含特异性结合gprc5d和cd3的双特异性抗体的药物组合物 | |
| EP4644422A1 (en) | Anti-nkg2a antibody and use thereof |